HOME INVESTOR RELATIONS INVESTOR RELATIONS By helping our clients to consistently outperform and build a strong foundation for the future, Cowen aims to deliver long-term value for our shareholders. SEE OUR LATEST RESULTS FINANCIALS Explore our SEC filings, corporate governance information and other shareholder information. Take a moment to read our latest Annual Report. QUICK LINKS Annual Report Quarterly earnings Latest news Stock chart update Historical price lookup Stockholder services Analyst Coverage Investor Presentations STAY UP TO DATE Financial tear sheet Cowen Investor Alerts GET IN TOUCH Cowen Investor inquiries will be routed to J.T. Farley, Managing Director and Head of Investor Relations. Name Email Message By submitting this form, you agree to being contacted with the above information. STOCK QUOTE COWN Exchange NASDAQ (USD) Price $35.56 Change -0.865 / -2.38% Volume 70,882 Data as of 12/03/2021 1:05 PM UTC. Minimum 15 minute delay. NEWS SEE ALL NEWS Acelyrin, Inc. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases NEWS NOV 29 2021 Private Equity Is Ready to Take MSP Consolidation to the Next Level READ THE ARTICLE “PRIVATE EQUITY IS READY TO TAKE MSP CONSOLIDATION TO THE NEXT LEVEL” READ MORE NEWS NOV 23 2021 Cowen to Acquire Portico Capital Advisors, Accelerating M&A Advisory Momentum in Strategic, Long-Term Growth Sectors READ THE ARTICLE “COWEN TO ACQUIRE PORTICO CAPITAL ADVISORS, ACCELERATING M&A ADVISORY MOMENTUM IN STRATEGIC, LONG-TERM GROWTH SECTORS” READ MORE NEWS NOV 17 2021 Acelyrin, Inc. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases READ THE ARTICLE “ACELYRIN, INC. CLOSES $250 MILLION SERIES B FINANCING AND ANNOUNCES LICENSING OF IZOKIBEP, A LATE-STAGE IL-17A INHIBITOR TO TREAT INFLAMMATORY DISEASES” READ MORE BOARD OF DIRECTORS Cowen’s Board of Directors is committed to strong corporate governance practices that emphasize oversight, transparency, accountability and stewardship. Their in-depth knowledge and diverse experiences serve management and shareholders alike. Jeffrey M. Solomon Chair and Chief Executive Officer, Cowen Inc. VIEW PROFILE Brett Barth Independent Director, Cowen Inc. VIEW PROFILE Katherine Elizabeth Dietze Independent Director, Cowen Inc. VIEW PROFILE Gregg A. Gonsalves Independent Director, Cowen Inc. VIEW PROFILE Steven Kotler Independent Director, Cowen Inc. VIEW PROFILE Lawrence Leibowitz Independent Director, Cowen Inc. VIEW PROFILE Jack H. Nusbaum In Memoriam, 1940 – 2021 VIEW PROFILE Margaret Poster Independent Director, Cowen Inc. VIEW PROFILE Douglas A. Rediker Independent Director, Cowen Inc. VIEW PROFILE COWN Exchange NASDAQ (USD) Price $35.56 Change -0.865 / -2.38% Volume 70,882 Data as of 12/03/2021 1:05 PM UTC. Minimum 15 minute delay. CAPABILITIES SECTORS GET TO KNOW COWEN JOIN OUR TEAM INVESTOR RELATIONS GET IN TOUCH Headquarters – New York +1-646-562-1010 info@cowen.com VIEW ALL LOCATIONS @Cowen_Inc @CowenResearch © 2021, Cowen Inc, All Rights Reserved Regulatory Disclosures FINRA Broker Check Terms of Use Notice for Non-U.S. Investors Privacy Manage Cookies